High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study).

Cresswell, Fiona V; Ssebambulidde, Kenneth; Grint, Daniel; Te Brake, Lindsey; Musabire, Abdul; Atherton, Rachel R; Tugume, Lillian; Muzoora, Conrad; Lukande, Robert; Lamorde, Mohammed; +4 more... Aarnoutse, Rob; Meya, David; Boulware, David R; Elliott, Alison M; (2018) High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). Wellcome open research, 3. 83-. ISSN 2398-502X DOI: https://doi.org/10.12688/wellcomeopenres.14691.1

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.12688/wellcomeopenres.14691.1

Abstract

Share

Download

Filename: Cresswell_etal_2018-high-dose-oral.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar